newsfilter
← Latest News
GlobeNewswire·

Scribe Therapeutics Announces Pricing of Upsized Initial Public Offering

SCTX
  • Scribe Therapeutics Inc. priced its upsized initial public offering of 8,580,000 common stock shares at $15.00 per share, the high end of the range.
  • The offering is expected to generate gross proceeds of $128.7 million before deducting underwriting discounts & commissions.
  • All shares in the public offering are being sold by Scribe Therapeutics, with underwriters granted a 30-day option to purchase up to an additional 1,287,000 shares.
  • Shares are scheduled to begin trading on the Nasdaq Global Market on July 24, 2026, under the symbol "SCTX."
  • The offering is expected to close on July 27, 2026, subject to customary closing conditions.
  • Joint book-running managers for the offering are Leerink Partners, Goldman Sachs & Co. LLC, Guggenheim Securities, & Wells Fargo Securities.
  • Scribe Therapeutics agreed to sell 500,000 shares at $15.00 per share in a concurrent private placement to Sanofi.
  • The private placement is unregistered under the Securities Act of 1933 & is expected to close on July 27, 2026, contingent on the IPO.
  • Scribe Therapeutics is a clinical-stage biotechnology company engineering in vivo CRISPR technologies to prevent cardiometabolic diseases such as ASCVD.
  • The company's lead candidate, STX-1150, is a liver-targeted therapy designed to epigenetically silence the PCSK9 gene to reduce LDL-C levels.
  • Scribe Therapeutics was co-founded by Nobel Prize winner Jennifer Doudna & has strategic collaborations with Sanofi & Eli Lilly.